- Home
- BB vs ZLAB Comparison
BB vs ZLAB Comparison
Compare BB & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BB | ZLAB |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BB | ZLAB |
|---|---|---|
| Price | $3.32 | $18.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $5.12 | ★ $49.44 |
| AVG Volume (30 Days) | ★ 4.9M | 544.8K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.91 | 38.46 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $534,900,000.00 | $460,156,000.00 |
| Revenue This Year | $4.19 | $14.46 |
| Revenue Next Year | $7.63 | $29.47 |
| P/E Ratio | $68.20 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $2.80 | $15.96 |
| 52 Week High | $5.32 | $44.34 |
Technical Indicators
Market Signals| Indicator | BB | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 44.52 |
| Support Level | $3.30 | $16.77 |
| Resistance Level | $3.59 | $19.71 |
| Average True Range (ATR) | 0.11 | 0.76 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 16.72 | 43.03 |
Price Performance
Historical ComparisonAbout BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.